Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

ePrints Soton (University of Southampton) 2026 Book

Authors: Asyl L. Hawa, Jo Picot, Lois Woods, Ines Ribeiro, Joanne L. Lord
Cited by: 0

Abstract

This report is a critique of the company’s submission (CS) to NICE from Merck on the clinical effectiveness and cost effectiveness of avelumab (Bavencio) in combination with axitinib (Inlyta) for treating adults with untreated advanced renal cell carcinoma (aRCC). It identifies the strengths and weakness of the CS.

Fields of Study & Subjects

Renal cell carcinoma treatment Health Systems Economic Evaluations Quality of Life Bladder and Urothelial Cancer Treatments

Publication details

Journal / source
ePrints Soton (University of Southampton)
Publication date
8 January 2026
Language
EN
Document type
Book